Effect of combined use of atorvastatin and hormonal therapy on serum prostate-specific antigen, urinary function, and quality of life of early prostate cancer patients in intensive care unit

Abstract

Purpose: To determine the effects of combined use of atorvastatin and hormonal therapy on serum levels of prostate-specific antigen (PSA), urinary function parameters, and quality of life (QOL) of intensive care unit (ICU) patients with early prostate cancer (PCa). Methods: The clinical data for 90 PCa patients treated in ICU of Chenzhou First People's Hospital, Chenzhou, China from July 2019 to July 2020 were retrospectively analyzed. The patients were divided into a reference group given intensity-modulated radiotherapy (n = 45), and a study group treated with intensity-modulated radiotherapy + atorvastatin + hormonal therapy (n = 45) sequentially as they were admitted. After the treatments, serum PSA levels of the patients were measured using enzyme-linked immunosorbent assay (ELISA), while QOL was measured based on Expanded Prostate Cancer Index Composite (EPIC). Urinary parameters were determined by measuring various urodynamic indicators. Results: Compared with the reference group, the study group had significantly lower post-treatment serum levels of PSA and blood lipids, higher levels of urinary function indicators (except for residual urine volume), and higher scores in IIEF-5 and EPIC (p < 0.001). Conclusion: These results demonstrate that the combined use of atorvastatin and hormonal therapy is a reliable method for improving urinary function and QOL in early PCa patients. Moreover, the combined treatment has potentials for reducing serum levels of PSA and blood lipids in PCa patients. These findings may be useful in the establishment of improved therapy for early PCa. Keywords: Atorvastatin; Hormonal therapy; Early prostate cancer; Serum PSA; Urinary function; Quality of life